Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01148966 · ClinicalTrials.gov registry record · Phase 1
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01148966 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT01148966, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of aminolevulinic acid during surgery in treating patients with malignant brain tumors. Aminolevulinic acid becomes active when it is exposed to a certain kind of light and may help doctors find and remove tumor cells during surgery
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE therapeutic conventional surgery
- DRUG aminolevulinic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01148966
The ClinicalTrials.gov registry entry for NCT01148966 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01148966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01148966 about?
NCT01148966 is a clinical study titled "Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors". This phase I trial is studying the side effects and best dose of aminolevulinic acid during surgery in treating patients with malignant brain tumors. Aminolevulinic acid becomes active when it is exposed to a certain kind of light and may help doctors find and remove tumor cells during surgery
What is the current status of trial NCT01148966?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-06.
What interventions are being tested in trial NCT01148966?
The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), aminolevulinic acid (DRUG).
Who is sponsoring clinical trial NCT01148966?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.